Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $56.35.

Several research firms recently weighed in on ZLAB. Citigroup reaffirmed a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the company an “outperform” rating in a research note on Monday, June 30th. Wall Street Zen cut shares of Zai Lab from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Finally, Jefferies Financial Group began coverage on shares of Zai Lab in a research note on Monday, August 25th. They set a “buy” rating and a $52.00 target price for the company.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares of the company’s stock, valued at $18,654,059.88. This trade represents a 8.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Yajing Chen sold 4,096 shares of Zai Lab stock in a transaction on Friday, August 8th. The stock was sold at an average price of $34.01, for a total transaction of $139,304.96. Following the completion of the transaction, the chief financial officer directly owned 16,908 shares of the company’s stock, valued at $575,041.08. The trade was a 19.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 215,710 shares of company stock valued at $7,589,684. Corporate insiders own 4.96% of the company’s stock.

Hedge Funds Weigh In On Zai Lab

Institutional investors and hedge funds have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. purchased a new position in shares of Zai Lab in the 1st quarter worth $603,000. BNP Paribas Financial Markets grew its stake in shares of Zai Lab by 1,439.8% in the 4th quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company’s stock worth $517,000 after buying an additional 18,472 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Zai Lab by 219.6% in the 1st quarter. Raymond James Financial Inc. now owns 125,967 shares of the company’s stock worth $4,552,000 after buying an additional 86,547 shares in the last quarter. Northern Trust Corp grew its stake in shares of Zai Lab by 117.8% in the 4th quarter. Northern Trust Corp now owns 49,365 shares of the company’s stock worth $1,293,000 after buying an additional 26,700 shares in the last quarter. Finally, Cerity Partners LLC purchased a new position in shares of Zai Lab in the 1st quarter worth $420,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Price Performance

Shares of NASDAQ ZLAB opened at $32.80 on Friday. The firm has a fifty day moving average price of $34.78 and a 200-day moving average price of $34.01. The stock has a market cap of $3.67 billion, a PE ratio of -16.08 and a beta of 1.04. Zai Lab has a 1 year low of $20.17 and a 1 year high of $44.34.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). The company had revenue of $109.98 million during the quarter, compared to analysts’ expectations of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. On average, research analysts expect that Zai Lab will post -2.58 EPS for the current year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.